Scotiabank Maintains Outperform for Merck & Co., Inc. (MRK) Feb 2026

On February 3, 2026 Scotiabank maintained an Outperform view on Merck & Co., Inc. (MRK) and raised its price target to $136 from $120, updating the MRK analyst rating. The action keeps a positive tilt while stopping short of an upgrade to Buy. Scotiabank’s move signals confidence in Merck’s drug pipeline and near-term earnings stability.

Scotiabank action and MRK analyst rating

Scotiabank on February 3, 2026 maintained an Outperform rating for Merck and raised its price target to $136 from $120. The note was reported by TheFly and flags stronger model assumptions behind Scotiabank’s valuation source.

What the MRK analyst rating means for investors

A maintained Outperform means Scotiabank still favors Merck relative to peers but does not change conviction. Investors should view the action as a vote of confidence in revenue drivers, not as a near-term catalyst call.

Impact on MRK stock performance and short-term reaction

Market reaction was modest with a reported intraday change of -0.54% (down $0.63) on the Scotiabank note. Recent quotes placed MRK near $116.20, as tracked by MarketWatch, showing the price target implies material upside from current levels source.

Historical coverage and context for MRK analyst rating

Merck has broad coverage from U.S. and global brokerages and typically sees mixed Buy/Outperform and Hold ratings. Scotiabank’s maintained Outperform continues a pattern of positive, but cautious, analyst sentiment toward the name.

Price target math and valuation implications

Scotiabank’s new price target of $136 implies an absolute upside of $19.80 from the $116.20 quote and a percentage upside of 17.04%. That gap frames the firm’s risk-reward view and sets a valuation benchmark for investors weighing entry points.

Meyka AI grade and market view on MRK analyst rating

Meyka AI rates MRK with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s real-time coverage and proprietary grade aim to give structured context to the MRK analyst rating while not serving as investment advice.

Final Thoughts

Scotiabank’s February 3, 2026 note maintained an Outperform on Merck & Co., Inc. (MRK) and lifted the price target to $136 from $120, updating the MRK analyst rating. The move signals continued analyst confidence in Merck’s core franchises and pipeline, and it creates a clear valuation reference showing $19.80 or 17.04% upside from the reported $116.20 level. For investors, the maintained Outperform is a supportive signal but not a prompt for immediate action; the upgrade in the price target suggests earnings or product expectations improved in Scotiabank’s model. Long-term holders should weigh the revised target against Merck’s dividend yield, pipeline milestones, and broader sector dynamics. Short-term traders should expect limited volatility tied solely to this note given the modest intraday price reaction. Meyka AI’s grade of B+ underlines relative strength versus peers while reminding readers that grades and ratings are informational and not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.